bioRxivCancer Biology
Development of an exosomal gene signature to detect residual disease in dogs with osteosarcoma using a novel xenograft platform and machine learning
K. Makielski, A. J. Donnelly, A. Khammanivong, M. C. Scott, A. R. Ortiz, D. C. Galvan, H. Tomiyasu, C. Amaya, K. Ward, A. Montoya, J. R. Garbe, L. J. Mills, G. R. Cutter, J. M. Fenger, W. C. Kisseberth, T. D. O'Brien, B. J. Weigel, L. G. Spector, B. A. Bryan, S. Subramanian, J. F. Modiano
Abstract
Osteosarcoma has a guarded prognosis. A major hurdle in developing more effective osteosarcoma therapies is the lack of disease-specific biomarkers to predict risk, prognosis, or therapeutic response. Exosomes are secreted extracellular microvesicles emerging as powerful diagnostic tools. However, their clinical application is precluded by challenges in identifying disease-associated cargo from the vastly larger background of normal exosome cargo. We developed a method using canine osteosarcoma in mouse xenografts to distinguish tumor-derived from host-response exosomal mRNAs. The model allows for the identification of canine osteosarcoma-specific gene signatures by RNA sequencing and a species-differentiating bioinformatics pipeline. An osteosarcoma-associated signature consisting of five gene transcripts (SKA2, NEU1, PAF1, PSMG2, and NOB1) was validated in dogs with spontaneous osteosarcoma by qRT-PCR, while a machine learning model assigned dogs into healthy or disease groups. Serum/plasma exosomes were isolated from 53 dogs in distinct clinical groups ("healthy", "osteosarcoma", "other bone tumor", or "non-neoplastic disease"). Pre-treatment samples from osteosarcoma cases were used as the training set and a validation set from post-treatment samples was used for testing, classifying as "osteosarcoma-detected" or "osteosarcoma-NOT detected". Dogs in a validation set whose post-treatment samples were classified as "osteosarcoma-NOT detected" had longer remissions, up to 15 months after treatment. In conclusion, we identified a gene signature predictive of molecular remissions with potential applications in the early detection and minimal residual disease settings. These results provide proof-of-concept for our discovery platform and its utilization in future studies to inform cancer risk, diagnosis, prognosis, and therapeutic response. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=147 SRC="FIGDIR/small/429432v2_ufig1.gif" ALT="Figure 1"> View larger version (41K): org.highwire.dtl.DTLVardef@1b612c4org.highwire.dtl.DTLVardef@8a1847org.highwire.dtl.DTLVardef@3ffd64org.highwire.dtl.DTLVardef@114df8c_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: mouse
- assay: bulk RNA-seq
- research focus: differential expression
- research focus: cell type annotation
- approach: machine learning (classical)
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A novel machine learning algorithm selects proteome signature to specifically identify cancer exosomes
Bingrui Li, Fernanda Grande Kugeratski, Raghu Kalluri·eLifePeer-reviewed·Oct 3, 2023
- Large Scale Comparative Deconvolution Analysis of the Canine and Human Osteosarcoma Tumor Microenvironment Uncovers Conserved Clinically Relevant Subtypes
S. A. Patkar, J. D. Mannheimer, … J. Beck·bioRxiv·Sep 27, 2023
- MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcoma.
Christopher B. Lietz, Cassandra C. Garbutt, … Dimitrios Spentzos·Scientific ReportsPeer-reviewed·Mar 10, 2020
- Prognosis prediction using autophagy gene expression in osteosarcoma
Qingzhu Liu, Cong Zhou, … Yihui Bi·bioRxiv·Nov 5, 2025
- Exosome derived multi-gene biomarker panel identifies the risk of liver metastasis in lung cancer patients
- Development and characterization of new patient-derived xenograft (PDX) models of osteosarcoma with distinct metastatic capacities
C. R. Schott, A. L. Koehne, … E. A. Sweet-Cordero·bioRxiv·Jan 19, 2023